Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
XGEN Venture is an Italian alternative investment fund manager (Società di Gestione del Risparmio, or SGR) founded in 2021 by the former Genextra team. The firm specializes in early-stage investments in private research and development companies within the life sciences sector. With over 15 years of experience in the startup ecosystem, XGEN Venture is dedicated to discovering and developing novel solutions for significant unmet medical needs. The firm is currently investing from its inaugural fund, the XGEN Venture Life Science Fund, which was launched at the end of 2022. This fund marks a significant milestone for the firm as it aims to support innovative healthcare solutions that can transform patient care and outcomes. XGEN Venture's reputation is built on its deep expertise in the biotech field, making it a trusted partner for startups looking to navigate the complexities of early-stage funding and development.
XGEN Venture focuses on early-stage investments in life sciences companies, specifically targeting private research and development firms that are working on innovative solutions to address significant medical needs. The firm is particularly interested in companies that are developing groundbreaking therapies in areas such as biotech and healthcare. Their investment strategy emphasizes the importance of supporting startups that are pioneering novel approaches to treatment, thereby enhancing the quality of life for patients. XGEN Venture typically invests at the pre-seed, seed, and seed-plus stages, allowing them to engage with companies from their inception and provide guidance throughout their growth journey. The firm seeks to partner with visionary founders who are committed to making a meaningful impact in the healthcare sector. By leveraging their extensive experience in the startup process, XGEN Venture aims to foster the development of transformative therapies that can address pressing medical challenges.
XGEN Venture's portfolio consists of 10 innovative companies that are making strides in the life sciences sector. Notable investments include **Epilepsy GTx**, which focuses on providing seizure freedom for patients with focal refractory epilepsy, and **AAVantgarde**, which develops next-generation therapies for inherited retinal diseases. Other significant portfolio companies include **GESYNTA PHARMA**, known for its non-hormonal treatments for endometriosis and inflammatory diseases, and **NANOPHORIA**, which pioneers inhalable cardiovascular treatments using non-viral, nano-in-micro delivery of biologics. Additionally, **iOnctura** is working on disrupting the tumor-stroma-immune interface for cancer treatment, while **Genespire** operates a gene therapy platform for rare diseases. Other key players in their portfolio include **Protembis**, **TES Pharma**, **Nouscom**, and **Page Therapeutics**, all of which are engaged in developing innovative solutions for various medical conditions. This diverse portfolio reflects XGEN Venture's commitment to supporting groundbreaking advancements in healthcare.
To pitch XGEN Venture, visit their website at xgenventure.com. They welcome pitches from founders, and it is recommended to include detailed information about your innovative solutions and the medical needs they address.
XGEN Venture has been actively involved in the life sciences space, with recent highlights including significant funding rounds for their portfolio companies. Notably, **Epilepsy GTx** secured $33 million in Series A funding, while **AAVantgarde** raised $141 million in Series B financing. These investments are aimed at advancing innovative therapies that address critical medical challenges.
XGEN Venture invests in early-stage companies, specifically at the pre-seed, seed, and seed-plus stages. This allows them to engage with startups from their inception and provide essential support as they grow.
Founders interested in pitching XGEN Venture can do so through their website at xgenventure.com. It is advisable to prepare a comprehensive pitch that outlines the innovative aspects of your solution and its potential impact on medical needs.
XGEN Venture primarily focuses on the life sciences sector, particularly in biotech and healthcare. They target companies that are developing innovative solutions to address significant medical needs.
The specific check size for investments by XGEN Venture is not disclosed in the available information. However, they typically invest at early stages, which may suggest smaller initial investments that can grow as companies progress.
XGEN Venture has a geographic focus on Europe, seeking to support innovative life sciences companies within this region.
XGEN Venture leverages its extensive experience in the startup process to provide valuable insights and resources to its portfolio companies, helping them navigate the complexities of development and funding.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.